Table 2.
Comparison of clinic‐pathologic features among patients with colorectal cancer with different MSS and HER2 mutation status
| Clinic‐pathologic features | HER2 mutation | MSI‐H without HER2 alteration (n = 2), n (%) | p value a | P value b | |
|---|---|---|---|---|---|
| MSS (n = 15), n (%) | MSI‐H (n = 14), n (%) | ||||
| Sex | |||||
| Female | 9 (60.0) | 3 (21.4) | 7 (29.2) | ||
| Male | 6 (40.0) | 11 (78.6) | 17 (70.8) | .035 | .60 |
| Age, yr | |||||
| Median | 56 | 47 | 42 | ||
| Mean ± SD | 52.5 ± 13.9 | 44.7 ± 14.9 | 42.8 ± 14.7 | .048 | .71 |
| Family history | |||||
| Yes | 3 (20.0) | 8 (57.1) | 12 (50.0) | ||
| No | 12 (80.0) | 6 (42.9) | 12 (50.0) | .039 | .67 |
| Location | |||||
| Right‐sided | 4 (26.7) | 6 (42.9) | 11 (45.8) | ||
| Left‐sided | 6 (40.0) | 6 (42.9) | 7 (29.2) | ||
| Rectum | 5 (33.3) | 2 (14.2) | 6 (25.0) | .44 | .61 |
| Grade | |||||
| Moderate + high differentiated | 10 (66.7) | 7 (50.0) | 11 (45.8) | ||
| Poorly + undifferentiated | 5 (33.3) | 7 (50.0) | 13 (54.2) | .36 | .80 |
| RAS | |||||
| Wild type | 8 (53.3) | 7 (50.0) | 11 (45.8) | ||
| Mutation | 7 (46.7) | 7 (50.0) | 13 (54.2) | .86 | .80 |
| TMB | |||||
| Median | 8.16 | 73.9 | 77.28 | ||
| Mean ± SD | 9.9 ± 4.7 | 99.3 ± 85.2 | 103.7 ± 114.8 | .0002 | .90 |
| TNM stage | |||||
| 0 | 0 (0) | 1 (7.1) | 5 (20.8) | ||
| I | 1 (6.7) | 0 (0) | 1 (4.2) | ||
| II | 0 (0) | 2 (14.3) | 6 (25.0) | ||
| III | 6 (40.0) | 3 (21.4) | 4 (16.7) | ||
| IV | 8 (53.3) | 8 (57.1) | 8 (33.3) | .29 | .49 |
| Metastatic sites | n = 14 | n = 10 | n = 11 | ||
| Liver | 6 (42.9) | 4 (40.0) | 4 (36.4) | .89 | .86 |
| Lung | 6 (42.9) | 0 (0) | 2 (18.2) | .017 | .16 |
| Distant lymph nodes | 5 (35.7) | 5 (50.0) | 4 (36.4) | .48 | .53 |
| Peritoneum | 7 (50.0) | 3 (30.0) | 6 (54.5) | .33 | .26 |
a
p comparison between MSI‐H group and MSS‐HER2 mutated group.
b
p comparison between MSS‐HER2 mutated group and HER2 amplification group.
Abbreviations: HER2, human epidermal growth factor receptor‐2; MSI‐H, microsatellite instability high; MSS, microsatellite stability; RAS, rat sarcoma viral oncogene homolog; TMB, tumor mutation burden; TNM, tumor‐node‐metastasis.